Cagrilintide

What is Cagrilintide?

Cagrilintide is a long-acting acylated analog of human amylin, a 37-amino acid peptide hormone co-secreted with insulin from pancreatic beta cells. Developed by Novo Nordisk, it activates amylin receptors in the area postrema and hindbrain regions involved in appetite regulation. The acyl chain modification extends its half-life to approximately 7 days, enabling once-weekly subcutaneous administration.

Amylin signaling complements GLP-1 pathways through distinct neuronal circuits. While GLP-1 agonists primarily affect hypothalamic appetite centers, amylin acts on the hindbrain to promote meal-related satiety, slow gastric emptying, and suppress postprandial glucagon secretion. This mechanistic distinction has made cagrilintide a candidate for combination therapy with semaglutide (CagriSema), where early data suggest additive weight loss benefits.

In the Phase 2 trial (NCT03856047), cagrilintide monotherapy at 4.5 mg produced mean body weight reductions of 10.8% at 26 weeks versus 3.0% with placebo. The combination of cagrilintide 2.4 mg with semaglutide 2.4 mg demonstrated 15.6% weight loss at 32 weeks in a Phase 1b study, outperforming semaglutide alone. Phase 3 trials (REDEFINE program) are ongoing.

Mechanism of Action

Cagrilintide's mechanism centers on amylin receptor activation in the central nervous system, providing appetite suppression through pathways distinct from GLP-1-based therapies.

Amylin Receptor Activation

Amylin receptors are heterodimers formed by the calcitonin receptor (CTR) complexed with receptor activity-modifying proteins (RAMPs). Cagrilintide binds these receptors in the area postrema and nucleus of the solitary tract (NTS) in the hindbrain, regions that integrate peripheral satiety signals. This activation reduces meal size and promotes early termination of feeding [1].

Gastric Emptying & Glucagon Suppression

Like native amylin (and its approved analog pramlintide), cagrilintide slows gastric emptying, extending the duration of post-meal satiety. It also suppresses postprandial glucagon secretion from pancreatic alpha cells, reducing hepatic glucose output after meals. These effects complement the insulinotropic actions of incretin-based therapies [3].

Distinct Neuronal Circuitry

A key advantage of amylin-based therapies is their activation of appetite circuits that do not fully overlap with GLP-1 pathways. While GLP-1 primarily signals through the hypothalamic arcuate nucleus (affecting NPY/AgRP and POMC neurons), amylin acts predominantly in the hindbrain. This mechanistic independence means that combining amylin and GLP-1 agonists can produce additive appetite suppression without simply doubling the same signal [2].

Long-Acting Pharmacokinetics

Native amylin has a plasma half-life of approximately 13 minutes, making it impractical for therapeutic use. The acyl chain modification in cagrilintide enables non-covalent binding to albumin in the circulation, extending the half-life to approximately 7 days. This allows once-weekly dosing while maintaining sustained receptor activation throughout the dosing interval.

Dosing Protocol

Cagrilintide uses a gradual escalation schedule to minimize gastrointestinal side effects, particularly nausea. The protocol below reflects the Phase 2 trial design.

Reconstitution Guide

Reconstitute lyophilized cagrilintide with bacteriostatic water. The peptide dissolves readily. Never shake the vial.

1. Remove the plastic cap from the vial and wipe the rubber stopper with an alcohol swab. Allow to dry completely.
2. Draw 2 mL of bacteriostatic water into a sterile syringe. For a 5 mg vial, this yields a concentration of 2.5 mg/mL.
3. Insert the needle through the rubber stopper at a slight angle. Inject the water slowly against the inner wall of the vial — do not spray directly onto the peptide powder.
4. Allow the vial to sit for 1–2 minutes. Gently roll the vial between your palms if needed. Do not shake or vortex.
5. The solution should be completely clear and colorless. Discard if you observe any cloudiness, particulate matter, or discoloration.

Injection Technique

Cagrilintide is administered via once-weekly subcutaneous injection. Standard SubQ technique applies.

1. Clean the injection site with an alcohol swab and allow it to air dry completely (approximately 30 seconds). Common sites: abdomen (2 inches from navel), upper thigh, or back of upper arm.
2. Draw the dose. Insert the needle into the vial through the rubber stopper. Invert the vial and draw the calculated number of units slowly. Tap the syringe to move any air bubbles to the top, then push them out gently.
3. Pinch the skin at the injection site to create a fold of subcutaneous tissue. Insert the needle at a 45-degree angle in a quick, smooth motion. Release the skin fold.
4. Inject slowly. Depress the plunger steadily over 5–10 seconds. Withdraw the needle at the same angle it was inserted. Apply gentle pressure with a clean swab if needed.

Storage & Stability

Cagrilintide should be stored properly to maintain potency throughout the dosing period.

Side Effects & Considerations

Cagrilintide's side effect profile shares some features with GLP-1 agonists (GI effects) but also includes amylin-specific considerations, particularly injection site reactions.

Commonly Reported

• Nausea — the most common side effect, reported in 26–47% of participants depending on dose. Generally mild-to-moderate and improving with continued use.
• Injection site reactions — nodules, erythema, and induration at the injection site. More frequent with cagrilintide than with GLP-1 agonists.
• Vomiting and diarrhea — transient, most common during dose escalation.
• Decreased appetite — a pharmacological effect central to the compound's weight loss mechanism.

Less Common

• Headache and dizziness during dose escalation, typically resolving with continued use.
• Potential for hypoglycemia when combined with insulin or insulin secretagogues. Amylin suppresses glucagon, which can compound the glucose-lowering effects of insulin.
• Abdominal distension or bloating from delayed gastric emptying.

Stacking Protocols

Cagrilintide's primary clinical development path is in combination with semaglutide (CagriSema). The distinct mechanisms of amylin and GLP-1 provide additive appetite suppression through non-overlapping neuronal pathways.

Cagrilintide + Semaglutide (CagriSema)

The flagship combination under investigation by Novo Nordisk. Cagrilintide acts on hindbrain amylin receptors while semaglutide acts on hypothalamic GLP-1 receptors, providing dual-pathway appetite suppression. Phase 1b data showed 15.6% weight loss at 32 weeks for the combination versus 8.1% for semaglutide alone.

Lifestyle Factors

As with all weight management compounds, lifestyle factors significantly influence outcomes:

• Protein intake: Adequate protein (1.2–1.6 g/kg) is critical during weight loss to preserve lean mass. Appetite suppression from cagrilintide may make it difficult to meet protein targets without conscious effort.
• Hydration: Delayed gastric emptying can reduce thirst cues. Maintain adequate fluid intake deliberately.
• Resistance training: Essential for lean mass preservation during rapid weight loss. At least 2–3 sessions per week recommended.
• Meal timing: Smaller, more frequent meals may improve tolerability given the compound's effects on gastric emptying.

Related Peptides

Researchers studying Cagrilintide often investigate these related compounds:

Literature & Citations

1. Lau DCW, Erichsen L, Francisco-Ziller N, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-comparator-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172. PubMed
2. Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286):1736-1748. PubMed
3. Lutz TA. Control of energy homeostasis by amylin. Cell Mol Life Sci. 2012;69(12):1947-1965. PubMed
4. Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: pharmacology, physiology, and clinical potential. Pharmacol Rev. 2015;67(3):564-600. PubMed
5. Roth JD, Roland BL, Cole RL, et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A. 2008;105(20):7257-7262. PubMed
6. Smith SR, Blundell JE, Burns C, et al. Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study. Am J Physiol Endocrinol Metab. 2007;293(2):E620-E627. PubMed